Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms

Ma, Jianying; Chi, Decai; Wang, Yan; Yan, Yubo; Song, Zhao; Liu, Huan; Jing, Jing; Pu, Haihong; Zhang, Minghui

doi:10.7150/jca.26155

Cited by 11 publications

(5 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results are consistent with other meta-analyses investigating the prognostic impact of PD-L1 tumor expression in NSCLC, all of which have found PD-L1 positivity to be inversely associated with survival (58)(59)(60)(61)(62). However, this is the first meta-analysis to focus only on resectable NSCLC tumors, and to exclude studies with tumors of patients diagnosed with metastatic disease.…”

Section: Discussionsupporting

confidence: 90%

PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis

Tuminello¹,

Sikavi²,

Veluswamy³

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background: PD-L1 tumor expression has been associated with poor prognosis in a variety of solid tumors, including lung cancer, and represents a validated target for immune checkpoint inhibition in advanced malignances. It remains unknown, however, if PD-L1 can be used to predict survival in early stage, surgically treated cancers. This meta-analysis compares PD-L1 tumor expression and long term survival after surgical resection in early non-small cell lung cancer (NSCLC).Methods: PubMed was searched to identify eligible studies that compared survival of surgically resected stage I-III NSCLC patients according to PD-L1 tumor expression. Included studies were grouped according to measurement criteria of PD-L1 expression: 1%, 5%, 50% cutoffs or H-score. Meta-analysis was performed using a linear mixed-effects model to determine overall survival (OS). I 2 was used as a measure of heterogeneity.Results: There were 40 eligible studies, including 10,380 patients. Regardless of cut-off used, higher PD-L1 tumor expression was associated with worse OS [hazard ratio (HR) 1% : 1.59, 95% confidence interval

show abstract

Section: Discussionsupporting

confidence: 90%

PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis

Tuminello¹,

Sikavi²,

Veluswamy³

et al. 2020

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…As regards tumor subtype, the present results showed that PD-L1 TIIC overexpression in adenocarcinoma was associated with poor DFS. This finding is consistent with a meta-analysis ( 35 ) and a cohort study ( 36 ) on PD-L1 in TC in pulmonary adenocarcinoma. However, the present study demonstrated that PD-L1 TIIC expression was associated with improved OS for patients with pulmonary squamous cell carcinoma.…”

Section: Discussionsupporting

confidence: 92%

Prognostic value of programmed cell death ligand‑1 expression in the tumor‑infiltrating immune cells of patients with lung cancer: A meta‑analysis

Berele

Yang

2021

Mol Clin Oncol

View full text Add to dashboard Cite

Several studies have investigated the prognostic significance of programmed cell death ligand 1 (PD-L1)-positive expression in the tumor cells (TC) of patients with lung cancer. However, tumor-infiltrating immune cell (TIIC)-based PD-L1 expression and its prognostic value remain controversial. The present meta-analysis was performed on 11 studies comprising 2,685 patients, which were identified by a systematic search on the PubMed, PMC, Web of Science and Embase databases. The databases were searched for published articles up to October 30, 2020. The studies that evaluated overall survival (OS) or disease-free survival (DFS) expressed as hazard ratios (HRs) in the PD-L1 TIIC of patients with lung cancer were analyzed. All statistical analyses were conducted using Stata software, version 16.0. The results demonstrated that PD-L1 expression in TIICs was not associated with OS [HR=0.98; confidence interval (CI)=0.73-1.33; P=0.53] and DFS (HR=1.05; CI=0.63-1.77; P=0.42) for all the cohort included in the study. However, subgroup analysis revealed that PD-L1 TIICs were associated with improved OS in lung squamous cell carcinoma (HR=0.76; CI=0.58-0.99; P=0.04), while poorer DFS was observed in lung adenocarcinoma (HR=1.30; CI=1.19-1.43; P=0.008) and at the >1% staining cutoff value (HR=1.56; CI=1.12-2.16; P=0.03). However, poor OS (P=0.21) and DFS (P=0.14) were observed in Asian populations, while DFS (P=0.07) for only-membrane staining was not statistically significant. The results of the present study suggested that adding PD-L1 TIICs to the existing diagnostic algorithm may help to guide patient selection for anti-PD-1/PD-L1 therapy. Future large-scale studies are warranted for confirmation of the present findings.

show abstract

“…The introduction of immune checkpoint inhibitors (ICIs) into breast oncology has been limited when compared to other cancers such as non-small cell lung (NSCLC), malignant melanoma, bladder and rectal cancers [92][93][94][95]. Currently, the IMPASSION 130 and Keynote 522 trials indicate promise with respect to the role of ICIs in treating TNBC in the early-stage (HR: 0.63, 95% CI: 0.43-0.99) and metastatic settings (HR: 0.80, 95% CI: 0.69-0.92) for combined ICI and conventional chemotherapy compared to placebo and chemotherapy [96,97].…”

Section: Ki-67 and Triple Negative Breast Cancermentioning

confidence: 99%

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

Davey

Hynes

Kerin

et al. 2021

Cancers

138

View full text Add to dashboard Cite

The advent of molecular medicine has transformed breast cancer management. Breast cancer is now recognised as a heterogenous disease with varied morphology, molecular features, tumour behaviour, and response to therapeutic strategies. These parameters are underpinned by a combination of genomic and immunohistochemical tumour factors, with estrogen receptor (ER) status, progesterone receptor (PgR) status, human epidermal growth factor receptor-2 (HER2) status, Ki-67 proliferation indices, and multigene panels all playing a contributive role in the substratification, prognostication and personalization of treatment modalities for each case. The expression of Ki-67 is strongly linked to tumour cell proliferation and growth and is routinely evaluated as a proliferation marker. This review will discuss the clinical utility, current pitfalls, and promising strategies to augment Ki-67 proliferation indices in future breast oncology.

show abstract

Prognostic value of PD-L1 expression in resected lung adenocarcinoma and potential molecular mechanisms

Cited by 11 publications

References 50 publications

PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis

PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis

Prognostic value of programmed cell death ligand‑1 expression in the tumor‑infiltrating immune cells of patients with lung cancer: A meta‑analysis

Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer

Contact Info

Product

Resources

About